Category: pharmacological
Aliases: Component of Mavyret
Pan-genotypic HCV NS5A inhibitor — blocks viral RNA replication and assembly. Co-formulated with glecaprevir as Mavyret. >97% sustained viral response across HCV genotypes 1–6 in 8-week treatment-naive regimens.
PO: 23h